The growing inclination for biologics and biosimilars is driving the sterile injectable contract manufacturing market.New ...

The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as ...

Charles Schwab Investment Management Inc. boosted its stake in Catalent, Inc. (NYSE:CTLT – Free Report) by 1.1% during the ...

Will the Novo-Catalent merger be challenged under the new Trump administration? A former FTC policy director thinks so.

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

Catalent (NYSE:CTLT) rose 2% amid a report that the European Union's antitrust regulator will likely grant approval for its ...

Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed ...

With a market cap of $10.7 billion, Catalent, Inc. (CTLT) is a leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products.

BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent (CTLT.N), opens new ...

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business ...

CIBC Asset Management Inc grew its holdings in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities ...